← Pharmacy curriculum
Module 476 submodulesAHA and ASA secondary stroke prevention guidance and current FDA labeling

Secondary Stroke Prevention

Translate stroke or TIA mechanism into durable recurrence prevention through diagnostic ownership, antithrombotic selection, source control, vascular-risk treatment, behavior support, and longitudinal surveillance.

01

Classify stroke and TIA mechanism using brain pattern, vascular anatomy, rhythm monitoring, cardiac evaluation, and focused alternative-cause testing.

02

Select single or short-course dual antiplatelet therapy for noncardioembolic events and document a safe duration and transition.

03

Choose and time anticoagulation for atrial fibrillation and other cardiac sources using infarct, hemorrhage, valve, organ function, interaction, and adherence data.

04

Apply evidence-based carotid, intracranial atherosclerosis, lipid, and blood-pressure strategies without substituting a procedure for medical therapy.

05

Use targeted pathways for PFO, ESUS, dissection, and small-vessel stroke while avoiding empiric escalation without a causal target.

06

Build a prevention system that supports behavior change, rehabilitation, access, adherence, recurrence recognition, and accountable follow-up.

47.01

Mechanism and Diagnostic Ownership

A prevention plan is only as specific as its causal model. Brain, arteries, heart, rhythm, exposure, and focused alternative-cause testing must converge on a defensible mechanism.

What to learn
  • Etiologic classification
  • TIA evaluation
  • Infarct pattern
  • Prolonged rhythm monitoring
  • Adherence assessment
Mechanism firstInfarct pattern, vessel imaging, cardiac evaluation, rhythm monitoring, and selective testing convert an event label into a prevention target.
01BrainPattern and territory

Lacunar, cortical, borderzone

02ArteryExtra and intracranial imaging

Plaque, stenosis, dissection

03HeartECG, monitoring, selective echo

AF, thrombus, valve, shunt

04OtherFocused cause testing

Do not order panels without a hypothesis

Treat TIA as an emergency mechanism warning

Transient focal symptoms can resolve while the causal stenosis, embolic source, or small-vessel process remains active. Evaluate brain tissue, extra and intracranial vessels, rhythm, pressure, glucose, and mimics urgently rather than waiting for a routine visit.

Read the infarct as a map, not a verdict

A cortical pattern raises embolic probability, a small deep infarct supports penetrating-vessel disease, a borderzone pattern raises hemodynamic questions, and multifocal territories suggest a proximal source. Each pattern changes probability but still requires vascular and cardiac correlation.

Search for AF in proportion to the question

Telemetry captures only a short interval. Ambulatory or implantable monitoring detects more paroxysmal AF when an embolic event remains unexplained. Choose duration according to pretest probability, patient feasibility, and whether detection would change anticoagulation.

Verify exposure before declaring failure

A medication listed in the chart may never have reached the patient. Reconstruct dispensing, administration, missed doses, swallowing, adverse effects, cost, cognition, beliefs, interactions, and caregiver support before changing therapy after recurrence.

0 of 1 answered
01A patient has a recurrent stroke while clopidogrel appears on the medication list. What should happen before labeling treatment failure?
Answer every question to submit.
47.02

Noncardioembolic Antiplatelet Therapy

Long-term single antiplatelet therapy is the default for noncardioembolic prevention, while dual therapy belongs to narrow early indications with an explicit stop date.

What to learn
  • Aspirin
  • Clopidogrel
  • Aspirin with extended-release dipyridamole
  • Short-course DAPT
  • Combination boundaries
Match drug to causeAntiplatelet therapy treats most noncardioembolic events, anticoagulation treats eligible cardioembolism, and combination duration must have a defined indication.
01SingleAspirin, clopidogrel, or aspirin dipyridamole

Long-term noncardioembolic prevention

02DualShort course in selected early minor stroke or TIA

Stop on schedule

03AnticoagAtrial fibrillation and selected cardiac sources

Time by infarct and bleeding

04AvoidRoutine antiplatelet plus anticoagulant

Bleeding without a prevention target

Select one durable antiplatelet strategy

Aspirin, clopidogrel, and aspirin with extended-release dipyridamole are established options. Selection depends on bleeding history, GI tolerance, allergy, headache, CYP2C19 interactions, formulation, swallowing, adherence, cost, and concurrent vascular indications.

Use early DAPT as a time-limited intervention

Aspirin plus clopidogrel reduces early recurrence in selected minor noncardioembolic stroke or high-risk TIA. Benefit is concentrated early, while bleeding rises with prolonged exposure. Document the qualifying event, start time, planned duration, and single-agent transition.

Treat severe symptomatic intracranial disease medically first

Aggressive medical management includes selected short-course DAPT, pressure control, intensive lipid lowering, diabetes and tobacco treatment, activity, and adherence. Routine intracranial angioplasty or stenting is not first-line recurrence prevention.

Do not stack antithrombotics without a second indication

Long-term DAPT is not routine, and antiplatelet plus anticoagulant therapy is usually not indicated solely for stroke prevention. A coronary stent, vascular procedure, or another condition may create a separate indication, but purpose and duration must remain explicit.

0 of 1 answered
01What is the most important safety action when starting DAPT after a qualifying minor stroke?
Answer every question to submit.
47.03

Cardioembolic Anticoagulation

Anticoagulation choice and timing require the embolic source, infarct biology, hemorrhage risk, valve status, organ function, product-specific dosing, interaction, and adherence context.

What to learn
  • Atrial fibrillation
  • Start timing
  • DOAC dosing
  • Mechanical valves
  • Ventricular thrombus
Cardioembolic preventionRhythm burden, valve type, ventricular or atrial thrombus, infarct size, hemorrhage risk, kidney function, and adherence determine anticoagulant and start time.
01DetectTelemetry and longer monitoring

More monitoring finds more AF

02SelectDOAC or warfarin by condition

Do not treat all valves alike

03TimeBalance early embolism and hemorrhage

Repeat imaging when needed

04SustainDose, interaction, access, adherence

Missed doses rapidly remove protection

Anticoagulate eligible atrial fibrillation

Most survivors with AF should receive anticoagulation when not contraindicated. Antiplatelet therapy alone does not provide equivalent cardioembolic protection. Rhythm evidence, infarct, hemorrhagic transformation, kidney and liver function, valve status, bleeding, interactions, adherence, and cost shape selection.

Time initiation to the brain, not only the rhythm

Early anticoagulation reduces the interval of recurrent embolic risk, but a large infarct or hemorrhagic transformation can make early treatment dangerous. Use neurologic severity, infarct size, imaging evolution, reperfusion exposure, bleeding, and repeat imaging rather than a universal start day.

Dose each DOAC as its own product

Apixaban, rivaroxaban, dabigatran, and edoxaban use different renal measures, reduction criteria, food instructions, interaction rules, and dosage forms. Calculate the required renal estimate and apply the current label. Unjustified underdosing can lose protection without eliminating bleeding.

Respect conditions that still require warfarin

Mechanical prosthetic valves require vitamin K antagonist therapy with valve-specific INR management. Ventricular thrombus requires coordinated treatment and repeat imaging. The medication, cardiac source, duration, monitoring, and concurrent antiplatelet need should never be inferred from the word cardioembolic alone.

0 of 1 answered
01Which patient should not be switched from warfarin to a DOAC for convenience?
Answer every question to submit.
47.04

Atherosclerotic and Structural Sources

Symptomatic carotid and intracranial disease demand causal localization and intensive medical therapy, with intervention chosen only for evidence-based anatomy and patient fit.

What to learn
  • Symptomatic carotid stenosis
  • CEA versus stenting
  • Intracranial stenosis
  • LDL lowering
  • Blood-pressure control
Atherosclerotic source controlCarotid and intracranial disease require aggressive medical therapy, with intervention reserved for evidence-based anatomy and patient selection.
01CarotidIpsilateral symptomatic stenosis

Early endarterectomy in suitable severe disease

02IntracranialAggressive risk and short DAPT

Stenting is not first line

03LipidHigh-intensity statin and LDL below 70

Add nonstatin when needed

04PressureUsually below 130 over 80

Individualize safely

Treat the symptomatic ipsilateral carotid lesion

Suitable patients with recent nondisabling stroke or TIA and severe ipsilateral extracranial carotid stenosis benefit from relatively early intervention. Confirm stenosis method, event territory, disability, timing, anatomy, medical therapy, life expectancy, and center outcomes.

Choose CEA or stenting through anatomy and risk

Endarterectomy and stenting differ in perioperative stroke, myocardial, cranial-nerve, access, and antiplatelet considerations. Age, arch and lesion anatomy, prior neck surgery or radiation, restenosis, cardiac disease, and operator performance determine the safer strategy.

Use aggressive medical therapy for intracranial disease

Severe symptomatic intracranial stenosis receives short-course DAPT when indicated plus intensive pressure, lipid, diabetes, tobacco, exercise, and adherence care. Routine angioplasty and stenting are not the first step, even when the image looks dramatic.

Control cumulative vascular exposure

For most survivors with atherosclerotic disease, use high-intensity statin therapy and an LDL goal below 70 mg/dL, adding ezetimibe and then considering a PCSK9 inhibitor when needed. A pressure goal below 130 over 80 is appropriate for most patients when safely tolerated.

0 of 1 answered
01What is first-line recurrence prevention for severe symptomatic intracranial atherosclerotic stenosis?
Answer every question to submit.
47.05

Special Mechanisms and Uncertain Source

PFO, ESUS, dissection, and small-vessel disease require specific causal reasoning. Uncertainty is a reason to maintain diagnostic ownership, not to escalate empirically.

What to learn
  • PFO closure
  • ESUS
  • Cervical dissection
  • Small-vessel disease
  • Focused testing
Special mechanismsPFO, ESUS, dissection, small-vessel disease, and unusual causes require targeted evidence rather than empiric escalation.
01PFOYounger selected nonlacunar stroke

Prove plausible causality

02ESUSDo not empirically anticoagulate

Continue diagnostic ownership

03DissectionAntithrombotic and vessel follow-up

Individualize bleeding and anatomy

04Small vesselPressure and vascular prevention

Do not search for a large embolus forever

Close only a plausibly causal PFO

PFO is common. Closure is reasonable in selected younger patients with a nonlacunar embolic event, no better cause, and higher-risk shunt anatomy. Complete vessel and rhythm evaluation and use neurology-cardiology shared decision-making that includes procedural AF and device risks.

Do not empirically anticoagulate ESUS

Embolic stroke of undetermined source is a diagnostic category, not a single disease. Trials do not support routine anticoagulation or ticagrelor for the group. Use antiplatelet therapy and continue targeted rhythm, cardiac, vascular, malignancy, and aortic evaluation when clinically justified.

Treat dissection as a wall injury

Cervical artery dissection differs from atherosclerotic carotid disease. Select antiplatelet or anticoagulant therapy according to infarct, anatomy, intracranial extension, pseudoaneurysm, bleeding, and patient context, then assign follow-up imaging and activity counseling.

Recognize small-vessel prevention

A compatible small deep infarct supports penetrating-vessel disease. Prevention centers on single antiplatelet therapy and intensive pressure, diabetes, lipid, tobacco, sleep, and activity care. Long-term DAPT adds bleeding without routine lacunar benefit.

0 of 1 answered
01What is the recommended empiric antithrombotic approach for ESUS without a defined cardioembolic source?
Answer every question to submit.
47.06

Lifelong Risk and Recurrence Care

A technically correct discharge list prevents little unless the patient can obtain, understand, perform, tolerate, monitor, and sustain the plan in daily life.

What to learn
  • Mediterranean-style diet
  • Safe physical activity
  • Tobacco treatment
  • Rehabilitation and mood
  • Access and recurrence response
Prevention that survives dischargeMedication, diet, activity, tobacco treatment, sleep, rehabilitation, cognition, mood, access, and repeated measurement determine whether a plan becomes durable protection.
01MeasurePressure, LDL, glucose, rhythm

Track control over time

02SupportBehavior change and rehabilitation

Advice alone is insufficient

03ReconcilePurpose, dose, duration, ownership

Investigate adherence before switching

04RespondNew symptoms trigger emergency care

TIA is not a routine visit

Use a behavior system, not advice alone

Low-sodium or Mediterranean-style eating, safe physical activity, tobacco cessation, sleep treatment, and medication adherence improve only when goals are specific, barriers are assessed, progress is measured, and multidisciplinary support continues. A brochure is not a longitudinal intervention.

Make activity and rehabilitation safe and possible

Mobility, language, vision, cognition, fatigue, pain, depression, and fear can limit prevention activity. Physical, occupational, speech, cognitive, swallowing, and psychological care should align with the patient's functional goals and environment.

Treat social conditions as clinical constraints

Cost, transportation, food access, housing, work, caregiving, health literacy, language, device access, and pharmacy availability shape exposure. Simplify regimens and connect real resources rather than documenting noncompliance without investigation.

Prepare for recurrence before it occurs

New focal symptoms are an emergency even if they resolve. Teach recognition, emergency activation, last-known-well recording, medication and bleeding information, and avoidance of self-directed extra antithrombotic doses. Assign follow-up for pending tests and risk targets.

0 of 1 answered
01Which intervention is most likely to produce durable behavior change after stroke?
Answer every question to submit.

Check the connections.

Each attempt draws 10 questions from the complete 104 question bank.

104 questions in this module bank10 questions per attempt

Each attempt draws a fresh set and rearranges the answer choices.

Current clinical foundation.

Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.

  1. AHA and ASA Secondary Stroke Prevention Guideline
  2. AHA Secondary Stroke Prevention Top Things to Know
  3. ACC Secondary Stroke Prevention Key Points
  4. DailyMed Current Antithrombotic Labeling
PharmacyOpen tools